TNFRSF4 and breast carcinoma: In an aggressive breast cancer model, the combination of OX40 agonism with CpG and an Fc-fused IL-12 protein injected intratumorally into tumors led to tumor regression of both treated and untreated contralateral tumors and significantly improved survival over vehicle-injected mice [19].